The FDA clears Aletta: the first robot that draws your blood without anyone holding its hand

The FDA authorized Aletta, the device from Dutch company Vitestro: the first autonomous robotic system capable of drawing blood without manual operator intervention. It did not arrive via the usual route of equivalence with an existing product, but through De Novo, the pathway reserved for devices so new that they do not fit into any prior classification. When the FDA uses De Novo, it is admitting something important: there was no box, so one had to be created.

That turns Aletta into the regulatory predicate for everything that comes after. Anyone wishing to launch a phlebotomy robot in the United States will no longer have to blaze a trail: they will have to compare themselves to Vitestro.

The system combines multimodal imaging—near-infrared, ultrasound, and Doppler—to locate the vein and, critically, distinguish it from an artery. Based on that reconstruction, AI-guided robotics calculates the needle's angle, depth, and trajectory in real time, adjusting if the vessel shifts.

And it executes the complete procedure: tourniquet placement, skin preparation, puncture, changing tubes, needle withdrawal, and dressing application. The healthcare professional presses a button and supervises. They do not hold the arm, do not search for the vein, do not repeat the stick.

Doppler is the elegant piece of the puzzle: it is what allows ruling out an arterial puncture, precisely the error that is most feared to automate.

On video, the complete sequence is better understood: the patient rests their arm, the system scans, decides, and executes.

The clinical evidence presented shows a success rate comparable to or higher than that of trained human phlebotomists, consistent results in patients with difficult venous access and across different skin tones, and rare and mild adverse events.

The point about skin tones is not a footnote: a significant portion of optical medical devices have historically failed because they were trained on poorly diverse populations. The fact that Aletta addresses this head-on is what lends credibility to the rest of the figures.

The underlying takeaway is more interesting than the device itself. Automation does not conquer the most complex jobs first, but rather the most repeatable, the most measurable, and those where hands are lacking. Phlebotomy had met all three requirements for decades: hundreds of millions of blood draws a year, a standardized protocol, objective success metrics, and a chronic shortage of personnel in laboratories and hospitals.

The FDA has not invented anything: it has signed off on the obvious. And that pattern is repeated across every sector. The same happened in the gaming industry: the first thing automated was not the commercial strategy of a hall, but chip counting, bill validation, and the calculation of progressive jackpots—repetitive, measurable, and critical tasks. When a process can be described with rules and audited with numbers, sooner or later it is executed by a machine.

What does not disappear is judgment. Aletta does not decide which lab test to order nor does it interpret the results: it flawlessly executes a well-defined task. As always, human labor is not eliminated; it shifts upward.